Krystal Biotech (NASDAQ:KRYS) Given New $218.00 Price Target at Chardan Capital

Krystal Biotech (NASDAQ:KRYS) had its price objective increased by Chardan Capital from $212.00 to $218.00 in a research report sent to investors on Thursday morning,Benzinga reports. Chardan Capital currently has a buy rating on the stock.

Several other research firms have also issued reports on KRYS. Citigroup increased their target price on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. HC Wainwright reiterated a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $210.00.

Krystal Biotech Trading Up 3.7 %

Shares of KRYS opened at $182.62 on Thursday. Krystal Biotech has a 12-month low of $107.50 and a 12-month high of $219.34. The firm has a market capitalization of $5.25 billion, a P/E ratio of 61.08 and a beta of 0.84. The firm has a 50-day moving average price of $157.18 and a 200 day moving average price of $175.18.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. The company had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company’s revenue for the quarter was up 116.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.30 earnings per share. Equities research analysts predict that Krystal Biotech will post 6.14 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the transaction, the insider now directly owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 14.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new stake in shares of Krystal Biotech during the fourth quarter worth $95,000. Palisades Investment Partners LLC lifted its position in Krystal Biotech by 9.3% during the fourth quarter. Palisades Investment Partners LLC now owns 40,479 shares of the company’s stock worth $6,341,000 after buying an additional 3,436 shares during the period. Woodline Partners LP boosted its stake in Krystal Biotech by 23.0% in the 4th quarter. Woodline Partners LP now owns 221,102 shares of the company’s stock worth $34,638,000 after buying an additional 41,287 shares during the last quarter. Soleus Capital Management L.P. grew its holdings in Krystal Biotech by 65.2% in the 4th quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company’s stock valued at $56,144,000 after buying an additional 141,400 shares during the period. Finally, ProShare Advisors LLC grew its holdings in Krystal Biotech by 28.6% in the 4th quarter. ProShare Advisors LLC now owns 8,848 shares of the company’s stock valued at $1,386,000 after buying an additional 1,967 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).